Clint T Allen

List of Publications by Citations

91 papers	2,561 citations	31 h-index	48 g-index
112 ext. papers	3,377 ext. citations	6.7 avg, IF	5.2 L-index

#	Paper	IF	Citations
91	Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. *Laryngoscope*, **2010**, 120, 1756-72	3.6	128
90	Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3K/ *Cancer Research*, **2017**, 77, 2607-2619	10.1	123
89	Np63 versatilely regulates a Broad NF-B gene program and promotes squamous epithelial proliferation, migration, and inflammation. *Cancer Research*, **2011**, 71, 3688-700	10.1	103
88	Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. *Clinical Cancer Research*, **2007**, 13, 3182-90	12.9	100
87	Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma. *Cancer Immunology Research*, **2017**, 5, 1141-1151	12.5	98
86	Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. *JCI Insight*, **2019**, 4,	9.9	95
85	Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. *Head and Neck*, **2007**, 29, 959-71	4.2	86
84	Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade. *Cancer Immunology Research*, **2016**, 4, 1061-1071	12.5	78
83	Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. *Oral Oncology*, **2016**, 58, 59-70	4.4	78
82	Aberrant IKK and IKK cooperatively activate NF-B and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer. *Oncogene*, **2014**, 33, 1135-47	9.2	67
81	Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. *Clinical Cancer Research*, **2020**, 26, 1420-1431	12.9	67
80	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. *Oncologist*, **2019**, 24, 1259-1269	5.7	67
79	Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer. *Clinical Cancer Research*, **2008**, 14, 4175-85	12.9	63
78	TNF- promotes c-REL/Np63 interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer. *Cancer Research*, **2011**, 71, 6867-77	10.1	59
77	Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells. *Oncotarget*, **2017**, 8, 55804-55820	3.3	58
76	Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors. *Cancer Immunology Research*, **2019**, 7, 401-413	12.5	57
75	PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. *OncoImmunology*, **2018**, 7, e1395996	7.2	57

74	Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. *Cancers*, **2015**, 7, 2397-414	6.6	51
73	Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. *Clinical Cancer Research*, **2009**, 15, 2361-72	12.9	50
72	Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib. *Radiology*, **2008**, 248, 485-91	20.5	50
71	Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers. *Cancer Immunology Research*, **2016**, 4, 611-20	12.5	50
70	Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. *Journal of Clinical Investigation*, **2019**, 129, 5553-5567	15.9	49
69	The clinical implications of antitumor immunity in head and neck cancer. *Laryngoscope*, **2012**, 122, 144-57	3.6	45
68	Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Anti-CD44-Based NIR-PIT. *Molecular Cancer Research*, **2017**, 15, 1667-1677	6.6	44
67	Laryngotracheal Stenosis: Risk Factors for Tracheostomy Dependence and Dilation Interval. *Otolaryngology - Head and Neck Surgery*, **2017**, 156, 321-328	5.5	41
66	The p53 homologue DeltaNp63alpha interacts with the nuclear factor-kappaB pathway to modulate epithelial cell growth. *Cancer Research*, **2008**, 68, 5122-31	10.1	40
65	PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations **2020**, 8,		40
64	Emerging insights into head and neck cancer metastasis. *Head and Neck*, **2013**, 35, 1669-78	4.2	37
63	Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer. *Otolaryngology - Head and Neck Surgery*, **2012**, 147, 493-500	5.5	36
62	mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer. *Oncotarget*, **2015**, 6, 36400-17	3.3	34
61	Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. *OncoImmunology*, **2018**, 7, e1466018	7.2	32
60	Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2010**, 77, 447-54	4	30
59	Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies **2018**, 6, 59		29
58	Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model. *Head and Neck*, **2017**, 39, 1086-1094	4.2	28
57	Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer. *OncoImmunology*, **2018**, 7, e1471440	7.2	25

56	The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis. *Laryngoscope*, **2018**, 128, E27-E32	3.6	24
55	Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function. *Cancer Immunology Research*, **2019**, 7, 282-291	12.5	24
54	Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS. *Arthritis and Rheumatology*, **2021**, 73, 1886-1895	9.5	24
53	WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy. *OncoImmunology*, **2018**, 7, e1488359	7.2	21
52	Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition. *OncoImmunology*, **2019**, 8, e1638207	7.2	21
51	Antigen processing and presentation in cancer immunotherapy **2020**, 8,		21
50	Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. *Oncotarget*, **2018**, 9, 4109-4119	3.3	19
49	Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. *ELife*, **2020**, 9,	8.9	19
48	Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. *Clinical Cancer Research*, **2020**, 26, 679-689	12.9	19
47	Endoscopic keel placement to treat and prevent anterior glottic webs. *Annals of Otology, Rhinology and Laryngology*, **2013**, 122, 672-8	2.1	18
46	Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer. *Oral Oncology*, **2017**, 71, 87-94	4.4	16
45	Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis **2019**, 7, 119		15
44	Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV and HPV Head and Neck Cancers to TNF, TRAIL, and Radiation Therapy. *Clinical Cancer Research*, **2019**, 25, 6463-6474	12.9	15
43	Murray secretion scale and fiberoptic endoscopic evaluation of swallowing in predicting aspiration in dysphagic patients. *European Archives of Oto-Rhino-Laryngology*, **2017**, 274, 2513-2519	3.5	14
42	Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells. *Oral Oncology*, **2019**, 90, 38-44	4.4	14
41	Pools of programmed death-ligand within the oral cavity tumor microenvironment: Variable alteration by targeted therapies. *Head and Neck*, **2016**, 38, 1176-86	4.2	14
40	Nanocomplex-based gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms. *OncoImmunology*, **2018**, 7, e1404216	7.2	13
39	Anatomic Derkay Score Is Associated with Voice Handicap in Laryngeal Papillomatosis in Adults. *Otolaryngology - Head and Neck Surgery*, **2016**, 154, 689-92	5.5	13

38	ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer. *OncoImmunology*, **2020**, 9, 1710398	7.2	13
37	Office-Based vs Traditional Operating Room Management of Recurrent Respiratory Papillomatosis: Impact of Patient Characteristics and Disease Severity. *JAMA Otolaryngology - Head and Neck Surgery*, **2017**, 143, 55-59	3.9	12
36	Avoiding phagocytosis-related artifact in myeloid derived suppressor cell T-lymphocyte suppression assays. *Journal of Immunological Methods*, **2017**, 440, 12-18	2.5	12
35	Clinical assessment and treatment of the dysfunctional larynx after radiation. *Otolaryngology - Head and Neck Surgery*, **2013**, 149, 830-9	5.5	11
34	Defining Clinical Subgroups in Relapsing Polychondritis: A Prospective Observational Cohort Study. *Arthritis and Rheumatology*, **2020**, 72, 1396-1402	9.5	9
33	Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer. *Head and Neck*, **2018**, 40, 1321-1334	4.2	9
32	Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials. *EBioMedicine*, **2021**, 67, 103345	8.8	9
31	How patients with an intact immune system develop head and neck cancer. *Oral Oncology*, **2019**, 92, 26-32	4.4	7
30	CCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer. *Clinical Cancer Research*, **2015**, 21, 942-3	12.9	7
29	Mechanisms of resistance to T cell-based immunotherapy in head and neck cancer. *Head and Neck*, **2020**, 42, 2722-2733	4.2	7
28	Hoarseness after metastatic colon cancer treatment. *JAMA Otolaryngology - Head and Neck Surgery*, **2014**, 140, 881-2	3.9	7
27	Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells **2021**, 9,		7
26	Evaluating the utility of serological testing in laryngotracheal stenosis. *Laryngoscope*, **2017**, 127, 1408-1412	3.1	4
25	Risk stratification in endoscopic airway surgery: is inpatient observation necessary?. *American Journal of Otolaryngology - Head and Neck Medicine and Surgery*, **2014**, 35, 747-52	2.8	3
24	The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma. *Biomarker Research*, **2021**, 9, 42	8	3
23	Prevalence of diabetes mellitus and its impact on disease severity in adult recurrent respiratory papillomatosis. *Otolaryngology - Head and Neck Surgery*, **2013**, 149, 603-7	5.5	2
22	Pathology quiz case 1. Primary diffuse large B-cell lymphoma of the larynx. *JAMA Otolaryngology*, **2011**, 137, 526, 528		2
21	Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in Macrophages. *Cancer Research*, **2021**, 81, 5977-5990	10.1	2

20	First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).. *Journal of Clinical Oncology*, **2021**, 39, TPS6092-TPS6092	2.2	2
19	Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis **2021**, 9,		2
18	Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes.. *Communications Biology*, **2021**, 4, 1416	6.7	2
17	A Submucosal True Vocal Fold Mass. *JAMA Otolaryngology - Head and Neck Surgery*, **2015**, 141, 1025-6	3.9	1
16	Tracheal mass. Malignant melanoma metastatic to the trachea. *JAMA Otolaryngology - Head and Neck Surgery*, **2015**, 141, 291-2	3.9	1
15	How Enhancing Immunity to Low-Risk HPV Could Cure Recurrent Respiratory Papillomatosis. *Laryngoscope*, **2021**, 131, 2041-2047	3.6	1
14	Biologics for the Treatment of Recurrent Respiratory Papillomatosis. *Otolaryngologic Clinics of North America*, **2021**, 54, 769-777	2	1
13	Immunotherapy for HPV Malignancies. *Seminars in Radiation Oncology*, **2021**, 31, 361-370	5.5	1
12	Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity.. *JCI Insight*, **2022**, 7,	9.9	1
11	Determining if T cell antigens are naturally processed and presented on HLA class I molecules.. *BMC Immunology*, **2022**, 23, 5	3.7	0
10	Trismus and voice change after starting tuberculosis treatment. *IDCases*, **2021**, 26, e01307	2	0
9	Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis. *Npj Vaccines*, **2021**, 6, 86	9.5	0
8	Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer.. *Biomarker Research*, **2021**, 9, 90	8	0
7	Squamous-cell carcinoma686-692		
6	Pathology quiz case 2. Lingual thyroid. *JAMA Otolaryngology*, **2010**, 136, 311, 313-4		
5	Immune Landscape and Role of Immunotherapy in Treatment of HPV-Associated Head and Neck Squamous Cell Carcinoma (HNSCC). *Current Otorhinolaryngology Reports*, **2022**, 10, 96	0.5	
4	Inflammation and Head and Neck Squamous Cell Carcinoma. *Current Cancer Research*, **2018**, 353-364	0.2	
3	Improving responses to immunotherapy in head and neck squamous cell carcinoma **2020**, 107-133		

2	Immunohistochemical analysis of NF-B in human tumor tissue. *Methods in Molecular Biology*, **2015**, 1280, 459-68	1.4
1	Posterior Subglottic Mass in a Patient With a History of Rectal Adenocarcinoma and Lung Metastases. *JAMA Oncology*, **2020**, 6, 1967-1968	13.4